Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 21, 2026
Last 12 months price action with 12-month analyst target path
As of March 5, 2026, Armata Pharmaceuticals, Inc. (ARMP) has a Wall Street consensus price target of $9.00, based on estimates from 4 covering analysts. With the stock currently trading at $11.61, this represents a potential downside of -22.5%. The company has a market capitalization of $42M.
Analyst price targets range from a low of $9.00 to a high of $9.00, representing a 0% spread in expectations. The median target of $9.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ARMP trades at a trailing P/E of -22.2x. Analysts expect EPS to grow +15.8% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ARMP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonARMP's consensus price target is $9, -22.5% below the current price of $11.61. The 4 analysts tracking ARMP see downside risk at present valuations.
ARMP has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $9 implies -22.5% downside from current levels.
ARMP's current price is $11.61 with a consensus target of $9 (-22.5% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $9 for ARMP, while the most conservative target is $9. The consensus of $9 represents the median expectation. These targets typically reflect 12-month expectations.
ARMP is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ARMP stock forecast based on 4 Wall Street analysts shows a consensus price target of $9, with estimates ranging from $9 (bear case) to $9 (bull case). The median consensus rating is "Buy".
Analysts are cautious on ARMP, with 0 Sell ratings and a price target of $9 (-22.5% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ARMP analyst price targets range from $9 to $9, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $9 consensus represents the middle ground.